Veradermics’ VDPHL01 Shows Promise in Hair Regrowth Trials
In a significant development for those experiencing hair loss, Veradermics’ oral minoxidil formulation, VDPHL01, has demonstrated positive results in Phase 2 and 3 clinical trials. If approved, VDPHL01 could become the first fresh prescription therapy for pattern hair loss in nearly 30 years, and the first oral prescription therapy approved by the FDA for women.
Understanding Pattern Hair Loss
Pattern hair loss, also known as androgenetic alopecia, is the most common cause of hair loss worldwide. It affects both men and women, though the presentation differs. Currently, treatment options are limited, with topical minoxidil (Rogaine) being a common over-the-counter solution, and finasteride available by prescription for men. However, topical minoxidil has variable response rates and a high discontinuation rate, with approximately 86% of patients stopping use within a year.
How VDPHL01 Works
VDPHL01 is an extended-release oral minoxidil tablet designed to address the limitations of existing treatments. Traditional, immediate-release oral minoxidil was initially developed for high blood pressure and isn’t optimized for hair regrowth. It reaches peak concentrations quickly but clears from the system rapidly, limiting its effectiveness. Immediate-release formulations have been associated with cardiac toxicities.
Veradermics utilized a proprietary extended-release technology to create VDPHL01, aiming to maintain consistent minoxidil exposure to hair follicles over a longer period. This approach seeks to maximize hair growth potential while minimizing the risk of cardiac side effects by avoiding concentration spikes.
Clinical Trial Results
Phase 2 and 3 trials are currently underway for both men and women. Initial results from a Phase 2/3 clinical trial in men with male pattern hair loss showed promising outcomes. Over six months, men taking VDPHL01, either once or twice daily, experienced an increase of between 30 and 33 more hairs per square millimeter.
What’s Next for VDPHL01?
Veradermics is continuing clinical trials to gather further data on the efficacy and safety of VDPHL01. The company anticipates that this work represents one of the most comprehensive clinical development programs undertaken for pattern hair loss to date. The potential approval of VDPHL01 could offer a new, convenient, and effective treatment option for the millions affected by hair loss.